ISRG stock forecast, quote, news & analysis
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery... Show more
Why Intuitive Surgical (ISRG) Is Down -4% in the Last 30 Days
Key Takeaways
- ISRG stock declined -4% over the past 30 days amid broader market rotation out of high-growth tech and healthcare names, despite strong Q4 2025 earnings.
- Over the past quarter, the stock fell -16%, reflecting tempered 2026 guidance for 13-15% da Vinci procedure growth versus 18% in 2025.
- Key drivers include macroeconomic pressures in Europe and potential U.S. healthcare funding changes, alongside analyst adjustments post-earnings.
- Robust demand for da Vinci systems persists, with Q4 revenue up 19% year-over-year and analysts raising 2026 EPS estimates to $10.06.
- Sector sentiment and capital constraints in key markets contributed to volatile, range-bound price action.
Intuitive Surgical (ISRG) Company Overview and Market Position
Intuitive Surgical, Inc. (ISRG) is a leading innovator in robotic-assisted minimally invasive surgery, best known for its da Vinci surgical systems. The company's core business model revolves around selling these systems to hospitals and generating recurring revenue from instruments, accessories, and services, which account for the majority of its income. Operating in the rapidly expanding robotic surgery industry, ISRG holds a dominant 60-70% market share globally, benefiting from high barriers to entry due to technological complexity and regulatory hurdles.
ISRG's strong fundamentals, including consistent double-digit procedure growth and high gross margins around 66-69%, underpin its premium valuation. Recent stock behavior reflects exposure to healthcare capital spending cycles and international macro trends, yet its installed base of over 11,000 systems supports resilient recurring revenue amid market volatility.
Intuitive Surgical (ISRG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ISRG stock declined approximately -4%, moving from around $500 to $480. The price action was volatile and range-bound, with intraday swings exceeding 3% on several days, including a drop to a 4-week low near $458 before partial recovery. This reflects choppy trading amid sector rotation and profit-taking.
For the past quarter, the stock fell -16%, from roughly $572 to $480. The decline accelerated post-Q4 earnings in late January, driven by a sustained downtrend with limited bounces, trading below both 50-day and 200-day moving averages near $510. Overall, performance has been trend-driven lower, underperforming the S&P 500.
What Drove ISRG Stock Price in the Last 30 Days
The 30-day decline stemmed primarily from broader market dynamics, including rotation out of high-valuation growth stocks like ISRG into value sectors such as utilities and energy. Despite no company-specific negative news, the stock faced pressure from elevated valuations—trading at over 60x trailing earnings—amid rising interest rate expectations and healthcare spending scrutiny.
Analyst sentiment remained mixed, with upgrades like Citi's to Buy but price target cuts reflecting caution. Procedure growth held steady, but short-term volatility tied to daily volume spikes and technical breakdowns below key supports amplified the downside. Macro influences, including European capital constraints, indirectly weighed on sentiment for ISRG's international exposure.
What Drove ISRG Stock Performance Over the Last Quarter
The quarterly drop was dominated by Intuitive Surgical's Q4 2025 earnings release on January 22, where revenue rose 19% to $2.87 billion and EPS hit $2.53, beating estimates. However, 2026 guidance for 13-15% da Vinci procedure growth—down from 18% in 2025—disappointed investors anticipating sustained acceleration.
Macroeconomic headwinds, including potential U.S. ACA subsidy changes, European fiscal pressures, Chinese competition, and Japanese capital equipment delays, factored into the outlook. Analyst downgrades, such as Citi to Neutral, and a 15% YTD pullback reflected valuation compression from peak levels near $600. Institutional selling and sector-wide healthcare derating amid inflation concerns had the strongest cumulative impact, pushing the stock into a downtrend.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds that analyze and trade thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum plays, optimized for different timeframes from intraday to long-term swings. Performance metrics like win rate, average return, and drawdown are transparently displayed, helping users identify relevant tools for stocks like ISRG. Whether seeking high-frequency scalpers or conservative position traders, the section highlights bots with proven edge in current market conditions. Explore Trending AI Robots to enhance your trading with data-backed automation.
ISRG Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings around late April for updates on procedure growth versus the 13-15% full-year guide, including U.S. general surgery trends and international adoption of da Vinci 5. Upcoming FDA expansions, such as cardiac applications, could broaden the addressable market.
Track macroeconomic shifts like healthcare funding reforms, European recovery, and tariff impacts on margins (estimated 1.2% revenue hit). Industry developments in robotic surgery competition and hospital capital budgets will influence system placements. Risks include prolonged macro pressures delaying growth, while catalysts like raised EPS estimates to $10.06 signal analyst optimism on long-term fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ISRG in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 27, 2026
ISRG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where ISRG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ISRG's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in of 332 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ISRG as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ISRG turned negative on April 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for ISRG moved below the 200-day moving average on March 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ISRG entered a downward trend on April 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.977) is normal, around the industry mean (8.059). P/E Ratio (57.258) is within average values for comparable stocks, (122.146). Projected Growth (PEG Ratio) (2.318) is also within normal values, averaging (2.342). ISRG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.019). P/S Ratio (16.234) is also within normal values, averaging (44.396).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther